Serum levels of anti-NS4a and anti-NS5a predict treatment response of patients with chronic hepatitis C

In order to understand better the clinical significance and prognostic value of antibody responses to HCV proteins and in search for parameters that may allow the early identification of non-sustained responders to therapy, antibody levels were measured against NS3, NS4a and NS5a at baseline in the serum of 120 patients chronically infected with HCV of genotype 1 that were classified as sustained responders relapsers, or non-responders to therapy. The capacity of these antibody tests to predict therapy-outcome was evaluated. While no differences were observed in the anti-NS3 responses in these different response groups, anti-NS4a and anti-NS5a antibodies were observed more frequently and at higher titres in sustained responders versus non-responders or non-sustained responders (-non-responders+relapsers). Based on this observation, a combination of test results consisting of 'the absence of NS4a (AA 16871718) antibody at baseline and the presence of HCV-RNA exceeding 105 IU/ml after 1 week of treatment' was identified which predicts nonsustained response to treatment with 100% certainty. Replacing the HCV-RNA decision limit by a HCV-core antigen level of > 15pg/ml resulted in the same predictive value. The proposed algorithm also holds for patients treated with peg-interferon and ribavirin. In conclusion, in patients with chronic HCV infection, the decision to continue or stop treatment can be made after 1 week of treatment with (peg)-interferon alpha and ribavirin. J. Med. Virol. 79:701-713, 2007. (C) 2007 Wiley-Liss, Inc.